Navigation Links
JDP Therapeutics, Inc. Appoints Christopher M. Cashman to Board of Directors
Date:6/18/2010

JDP Therapeutics, Inc., a specialty pharmaceutical company, announced today the appointment of Christopher M. Cashman to its Board of Directors. Mr. Cashman has an impressive track record in heading start-up pharmaceutical companies and advancing them to exit in addition to having over 30 years of industry experience.

Lansdale, Pennsylvania (PRWEB) June 18, 2010 -- JDP Therapeutics, Inc., a specialty pharmaceutical company, announced today the appointment of Christopher M. Cashman to its Board of Directors. Mr. Cashman has an impressive track record in heading start-up pharmaceutical companies and advancing them to exit in addition to having over 30 years of industry experience.

"Chris has been an invaluable advisor to JDP since its inception working along side founder Jie Du, Ph.D. for the past two years. He has played an integral role in the company’s success to date and we are thrilled that Chris has decided to become a formal member of the team,” said Josh Tarnoff, JDP’s CEO and Executive Board Member. “On a personal note, he is highly respected and well known for his strong integrity and relationships in both the corporate and investment communities.”

Christopher Cashman is co-founder of Protez Pharmaceuticals Inc. and served as Director, President and CEO. Protez was acquired by Novartis in 2008. He was the recipient of the “Entrepreneur of the Year” award at the 2008 MAC Alliance Conference and the “Life Sciences CEO of the Year” by the Eastern Technology Council. He currently also serves on the Board of Directors of Noble Biomaterials, MBF Therapeutics and the Science Center.

“It has been a pleasure working with Jie on the start-up phase of JDP, and now with Josh on board as CEO, JDP is well positioned to advance JDP-205 into the clinic,” said Mr. Cashman.

Company founder Jie Du, Ph.D. added, “The timing for Chris to join our team is especially fitting as we are now poised to move our flagship product into Phase I clinical trial development. We are excited that he will continue to share in our growth and help guide the Board through this very important phase.”

JDP Therapeutics Inc., founded in 2008, is a specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for acute care use in the hospital setting.

For further information, please call 215-661-8557 or email info(at)jdptherapeutics(dot)com.

###

Read the full story at http://www.prweb.com/releases/JDP_Therapeutics/Pharmaceuticals/prweb4159384.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Osseon Therapeutics, Inc. Announces it has Received Canadian Medical Device Licenses From Health Canada
2. Cell Therapeutics, Inc. (CTI) Piper Jaffray Presentation to be Webcast
3. EWI Worldwide Appoints Matt Hubbard President, Exhibit Works Division
4. Digital Pathology Services Firm Flagship Biosciences Appoints New CEO
5. Providence Hospital Appoints Four New Members to its Board of Directors
6. iSirona Appoints Chief Quality and Regulatory Officer to Oversee Quality Initiatives
7. Connectyx Technologies Holdings Group, Inc. Appoints Dr. James R. Taylor to Its Board of Advisors
8. Trinity Health Appoints Four to Board of Directors Trinity Health Appoints Four to Board of Directors
9. GeoVax Labs Appoints Two Industry Veterans to Board of Directors
10. Bon Secours Charity Health System Appoints Philip A. Patterson As CEO
11. Touro Appoints Alan Kadish, M.D. President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s Home ... University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. , ...
(Date:4/28/2017)... Clara, CA (PRWEB) , ... April 28, 2017 ... ... is pleased to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep ... user experience, since it streamlines the reporting process and provides a familiar interface ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, ... the GlycoMark test throughout the Northeast U.S. , GlycoMark is the only ... The GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic ...
(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that ... Conference 2017 at the Sheraton Hotel in Toronto, Ontario ... of the Company is scheduled to present on Tuesday, May 2 ... the Chairman of the Board, Tony Holler will also ... For more ...
Breaking Medicine Technology: